N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer

Cancer Cell

Volumn 30, Issue 4, 2016, Pages 563-577

  Dardenne, Etienne ^a   Beltran, Himisha ^a   Benelli, Matteo ^b   Gayvert, Kaitlyn ^a   Berger, Adeline ^a   Puca, Loredana ^a   Cyrta, Joanna ^a   Sboner, Andrea ^a   Noorzad, Zohal ^a   MacDonald, Theresa ^a   Cheung, Cynthia ^a   Yuen, Ka Shing ^a   Gao, Dong ^c   Chen, Yu ^a,c   Eilers, Martin ^d   Mosquera, Juan Miguel ^a   Robinson, Brian D ^a   Elemento, Olivier ^a   Rubin, Mark A ^a   Demichelis, Francesca ^a,b   Rickman, David S ^a   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TRENTO   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Aurora kinase A; castration resistant prostate adenocarcinoma; EZH2; genetically engineered mouse; N Myc; neuroendocrine prostate cancer; prostate cancer organoid

Indexed keywords

ANDROGEN RECEPTOR; MYC PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTOME; ALISERTIB; AZEPINE DERIVATIVE; EZH2 PROTEIN, HUMAN; EZH2 PROTEIN, MOUSE; MYCN PROTEIN, HUMAN; MYCN PROTEIN, MOUSE; N MYC PROTO ONCOGENE PROTEIN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; ENHANCER REGION; GENE AMPLIFICATION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; MOUSE MODEL; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; METABOLISM; NEUROENDOCRINE TUMORS; ONCOGENE MYC; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; AZEPINES; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENES, MYC; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, TRANSGENIC; N-MYC PROTO-ONCOGENE PROTEIN; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84991790827     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.09.005     Document Type: Article

References (50)

1. Althoff, K., Beckers, A., Bell, E., Nortmeyer, M., Thor, T., Sprussel, A., Lindner, S., De Preter, K., Florin, A., Heukamp, L.C., et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene 34 (2015), 3357–3368.
2. Beltran, H., Rickman, D.S., Park, K., Chae, S.S., Sboner, A., MacDonald, T.Y., Wang, Y., Sheikh, K.L., Terry, S., Tagawa, S.T., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1 (2011), 487–495.
3. Beltran, H., Prandi, D., Mosquera, J.M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B.V., Varambally, S., et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22 (2016), 298–305.
4. Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H.E., Rycak, L., Jamin, Y., Thway, K., Robinson, S.P., Roels, F., et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24 (2013), 75–89.
5. Brognard, J., Sierecki, E., Gao, T., Newton, A.C., PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25 (2007), 917–931.
6. Cancer Genome Atlas Research Network, The molecular taxonomy of primary prostate cancer. Cell 163 (2015), 1011–1025.
7. Carver, B.S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V.K., Le, C., Koutcher, J., Scher, H., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19 (2011), 575–586.
8. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
9. Chen, H., Sun, Y., Wu, C., Magyar, C.E., Li, X., Cheng, L., Yao, J.L., Shen, S., Osunkoya, A.O., Liang, C., Huang, J., Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr. Relat. Cancer 19 (2012), 321–331.
10. Chen, Y., Chi, P., Rockowitz, S., Iaquinta, P.J., Shamu, T., Shukla, S., Gao, D., Sirota, I., Carver, B.S., Wongvipat, J., et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat. Med. 19 (2013), 1023–1029.
11. Chesler, L., Schlieve, C., Goldenberg, D.D., Kenney, A., Kim, G., McMillan, A., Matthay, K.K., Rowitch, D., Weiss, W.A., Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66 (2006), 8139–8146.
12. Dauch, D., Rudalska, R., Cossa, G., Nault, J.C., Kang, T.W., Wuestefeld, T., Hohmeyer, A., Imbeaud, S., Yevsa, T., Hoenicke, L., et al. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat. Med. 22 (2016), 744–753.
13. Gao, D., Vela, I., Sboner, A., Iaquinta, P.J., Karthaus, W.R., Gopalan, A., Dowling, C., Wanjala, J.N., Undvall, E.A., Arora, V.K., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159 (2014), 176–187.
14. Gao, D., Zhan, Y., Di, W., Moore, A.R., Sher, J.J., Guan, Y., Wang, S., Zhang, Z., Murphy, D.A., Sawyers, C.L., et al. A Tmprss2-CreERT2 knock-in mouse model for Cancer genetic studies on prostate and colon. PLoS One, 11, 2016, e0161084.
15. Grimmer, M.R., Weiss, W.A., Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediatr. 18 (2006), 634–638.
16. Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., Chen, J., Benes, C., Charron, E., Simonds, E.F., Seeger, R., Matthay, K.K., Hertz, N.T., et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26 (2014), 414–427.
17. Hieronymus, H., Lamb, J., Ross, K.N., Peng, X.P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S.M., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10 (2006), 321–330.
18. Humphrey, P.A., Histological variants of prostatic carcinoma and their significance. Histopathology 60 (2012), 59–74.
19. Ito, T., Yamamoto, S., Ohno, Y., Namiki, K., Aizawa, T., Akiyama, A., Tachibana, M., Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol. Rep. 8 (2001), 1221–1224.
20. Karthaus, W.R., Iaquinta, P.J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., Dowling, C.M., Gao, D., Begthel, H., Sachs, N., et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159 (2014), 163–175.
21. Khaw, Y.L., Nolan, N., Heaslip, I., McCormick, P.A., Sheahan, K., Primary intrahepatic small-cell carcinoma arising from combined hepatocellular and cholangiocarcinomas. J. Clin. Oncol. 29 (2011), e630–633.
22. Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N., Wang, W., Haswell, J.R., Walensky, L.D., Hahn, W.C., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21 (2015), 1491–1496.
23. Koh, C.M., Iwata, T., Zheng, Q., Bethel, C., Yegnasubramanian, S., De Marzo, A.M., Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2 (2011), 669–683.
24. Lee, J.K., Phillips, J.W., Smith, B.A., Park, J.W., Stoyanova, T., McCaffrey, E.F., Baertsch, R., Sokolov, A., Meyerowitz, J.G., Mathis, C., et al. N-myc drives neuroendocrine prostate Cancer initiated from human prostate epithelial cells. Cancer Cell 29 (2016), 536–547.
25. Lotan, T.L., Gupta, N.S., Wang, W., Toubaji, A., Haffner, M.C., Chaux, A., Hicks, J.L., Meeker, A.K., Bieberich, C.J., De Marzo, A.M., et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24 (2011), 820–828.
26. Martin, P., Liu, Y.N., Pierce, R., Abou-Kheir, W., Casey, O., Seng, V., Camacho, D., Simpson, R.M., Kelly, K., Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am. J. Pathol. 179 (2011), 422–435.
27. Mosquera, J.M., Beltran, H., Park, K., MacDonald, T.Y., Robinson, B.D., Tagawa, S.T., Perner, S., Bismar, T.A., Erbersdobler, A., Dhir, R., et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15 (2013), 1–10.
28. Mott, L.J., Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature. J. Urol. 121 (1979), 833–835.
29. Mulholland, D.J., Tran, L.M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I.P., Huang, J., Graeber, T.G., Wu, H., Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19 (2011), 792–804.
30. Nelson, P.S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., Lin, B., The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. USA 99 (2002), 11890–11895.
31. Otto, T., Horn, S., Brockmann, M., Eilers, U., Schuttrumpf, L., Popov, N., Kenney, A.M., Schulte, J.H., Beijersbergen, R., Christiansen, H., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15 (2009), 67–78.
32. Parwani, A.V., Kronz, J.D., Genega, E.M., Gaudin, P., Chang, S., Epstein, J.I., Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am. J. Surg. Pathol. 28 (2004), 651–657.
33. Ratajczak, T., Cluning, C., Ward, B.K., Steroid receptor-associated immunophilins: a gateway to steroid signalling. Clin. Biochem. Rev. 36 (2015), 31–52.
34. Ratajczak, T., Ward, B.K., Minchin, R.F., Immunophilin chaperones in steroid receptor signalling. Curr. Top Med. Chem. 3 (2003), 1348–1357.
35. Robinson, D., Van Allen, E.M., Wu, Y.M., Schultz, N., Lonigro, R.J., Mosquera, J.M., Montgomery, B., Taplin, M.E., Pritchard, C.C., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
36. Scheble, V.J., Braun, M., Beroukhim, R., Mermel, C.H., Ruiz, C., Wilbertz, T., Stiedl, A.C., Petersen, K., Reischl, M., Kuefer, R., et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol. 23 (2010), 1061–1067.
37. Schlaeger, C., Longerich, T., Schiller, C., Bewerunge, P., Mehrabi, A., Toedt, G., Kleeff, J., Ehemann, V., Eils, R., Lichter, P., et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 47 (2008), 511–520.
38. Shachaf, C.M., Kopelman, A.M., Arvanitis, C., Karlsson, A., Beer, S., Mandl, S., Bachmann, M.H., Borowsky, A.D., Ruebner, B., Cardiff, R.D., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 (2004), 1112–1117.
39. Shen, R., Dorai, T., Szaboles, M., Katz, A.E., Olsson, C.A., Buttyan, R., Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol. Oncol. 3 (1997), 67–75.
40. Sjostrom, S.K., Finn, G., Hahn, W.C., Rowitch, D.H., Kenney, A.M., The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev. Cell 9 (2005), 327–338.
41. Small, E.J., Aggarwal, R.R., Huang, J., Sokolov, A., Zhang, L., Alumkal, J.J., Youngren, J., Ryan, C.J., Foye, A., Reiter, R.E., et al. Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT). J. Clin. Oncol., 34(suppl), 2016 abstr 5019.
42. Tan, H.L., Sood, A., Rahimi, H.A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C.D., Epstein, J.I., Netto, G.J., et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20 (2014), 890–903.
43. Wang, H.T., Yao, Y.H., Li, B.G., Tang, Y., Chang, J.W., Zhang, J., Neuroendocrine prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J. Clin. Oncol. 32 (2014), 3383–3390.
44. Williamson, S.R., Zhang, S., Yao, J.L., Huang, J., Lopez-Beltran, A., Shen, S., Osunkoya, A.O., MacLennan, G.T., Montironi, R., Cheng, L., ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod. Pathol. 24 (2011), 1120–1127.
45. Wright, M.E., Tsai, M.J., Aebersold, R., Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol. Endocrinol. 17 (2003), 1726–1737.
46. Wu, X., Wu, J., Huang, J., Powell, W.C., Zhang, J., Matusik, R.J., Sangiorgi, F.O., Maxson, R.E., Sucov, H.M., Roy-Burman, P., Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101 (2001), 61–69.
47. Xu, K., Wu, Z.J., Groner, A.C., He, H.H., Cai, C., Lis, R.T., Wu, X., Stack, E.C., Loda, M., Liu, T., et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338 (2012), 1465–1469.
48. Yuan, T.C., Veeramani, S., Lin, F.F., Kondrikou, D., Zelivianski, S., Igawa, T., Karan, D., Batra, S.K., Lin, M.F., Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr. Relat. Cancer 13 (2006), 151–167.
49. Zhang, W., Yu, Y., Hertwig, F., Thierry-Mieg, J., Zhang, W., Thierry-Mieg, D., Wang, J., Furlanello, C., Devanarayan, V., Cheng, J., et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol., 16, 2015, 133.
50. Zhou, Z., Flesken-Nikitin, A., Corney, D.C., Wang, W., Goodrich, D.W., Roy-Burman, P., Nikitin, A.Y., Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 66 (2006), 7889–7898.